Kwangwoo Nam1,2, Sang Hyoung Park3, Jun Ho Oh4, Ho-Su Lee5, Soomin Noh2, Jae Cheol Park2, Jin Yong Kim2, Eun Hye Oh2, Jeongseok Kim2, Nam Seok Ham2, Sung Wook Hwang2, Dong-Hoon Yang2, Byong Duk Ye2, Jeong-Sik Byeon2, Seung-Jae Myung2, Suk-Kyun Yang2. 1. Department of Gastroenterology, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea. 2. Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. 3. Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. umdalpin@hanmail.net. 4. University of Ulsan College of Medicine, Seoul, Korea. 5. Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine, Seoul, Korea.
Abstract
BACKGROUND: Many patients with ulcerative colitis (UC) in clinical remission frequently complain of bowel symptoms such as increased stool frequency (SF) and rectal bleeding (RB). However, studies on these patient-reported outcomes in patients with inactive UC are limited, especially in Korea. Therefore, we investigated the prevalence and risk factors of bowel symptoms in Korean patients with inactive UC. METHODS: We investigated the prevalence of bowel symptoms in patients with endoscopically quiescent UC between June 1989 and December 2016 using a well-characterized referral center-based cohort. The Mayo clinic score (MCS) was used to evaluate bowel symptoms at the most recent visit near the date of endoscopy. Clinical characteristics of the patients were compared based on the presence or absence of bowel symptoms. RESULTS: Overall, 741 patients with endoscopically quiescent UC were identified, of whom 222 (30%) and 48 (6.5%) had an SF and RB subscore of ≥ 1, respectively. Patients with bowel symptoms (SF + RB ≥ 1; n = 244 [32.9%]) had higher rates of left-sided colitis (E2) or extensive colitis (E3) than patients without bowel symptoms (SF + RB = 0; n = 497 [67.1%]; P = 0.002). Multivariate analysis revealed that female sex (odds ratio [OR]: 1.568; 95% confidence interval [CI]: 1.023-2.402; P = 0.039) and E2 or E3 (OR 1.411; 95% CI 1.020-1.951; P = 0.038) were the significant risk factors for increased SF. CONCLUSIONS: This study revealed that one-third of patients with endoscopically quiescent UC reported increased SF. Female sex and disease extent may be associated with bowel symptoms.
BACKGROUND: Many patients with ulcerative colitis (UC) in clinical remission frequently complain of bowel symptoms such as increased stool frequency (SF) and rectal bleeding (RB). However, studies on these patient-reported outcomes in patients with inactive UC are limited, especially in Korea. Therefore, we investigated the prevalence and risk factors of bowel symptoms in Korean patients with inactive UC. METHODS: We investigated the prevalence of bowel symptoms in patients with endoscopically quiescent UC between June 1989 and December 2016 using a well-characterized referral center-based cohort. The Mayo clinic score (MCS) was used to evaluate bowel symptoms at the most recent visit near the date of endoscopy. Clinical characteristics of the patients were compared based on the presence or absence of bowel symptoms. RESULTS: Overall, 741 patients with endoscopically quiescent UC were identified, of whom 222 (30%) and 48 (6.5%) had an SF and RB subscore of ≥ 1, respectively. Patients with bowel symptoms (SF + RB ≥ 1; n = 244 [32.9%]) had higher rates of left-sided colitis (E2) or extensive colitis (E3) than patients without bowel symptoms (SF + RB = 0; n = 497 [67.1%]; P = 0.002). Multivariate analysis revealed that female sex (odds ratio [OR]: 1.568; 95% confidence interval [CI]: 1.023-2.402; P = 0.039) and E2 or E3 (OR 1.411; 95% CI 1.020-1.951; P = 0.038) were the significant risk factors for increased SF. CONCLUSIONS: This study revealed that one-third of patients with endoscopically quiescent UC reported increased SF. Female sex and disease extent may be associated with bowel symptoms.
Authors: Ami D Sperber; Dan Dumitrascu; Shin Fukudo; Charles Gerson; Uday C Ghoshal; Kok Ann Gwee; A Pali S Hungin; Jin-Yong Kang; Chen Minhu; Max Schmulson; Arkady Bolotin; Michael Friger; Tamar Freud; William Whitehead Journal: Gut Date: 2016-01-27 Impact factor: 23.059
Authors: Jean Frédéric Colombel; Paul Rutgeerts; Walter Reinisch; Dirk Esser; Yanxin Wang; Yinghua Lang; Colleen W Marano; Richard Strauss; Björn J Oddens; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Daniel Present; Bruce E Sands; William J Sandborn Journal: Gastroenterology Date: 2011-06-30 Impact factor: 22.682
Authors: Meenakshi Bewtra; Colleen M Brensinger; Vesselin T Tomov; Tram B Hoang; Carly E Sokach; Corey A Siegel; James D Lewis Journal: Inflamm Bowel Dis Date: 2014-06 Impact factor: 5.325
Authors: L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel Journal: Am J Gastroenterol Date: 2015-08-25 Impact factor: 10.864
Authors: Jean-Frédéric Colombel; Mary E Keir; Alexis Scherl; Rui Zhao; Gert de Hertogh; William A Faubion; Timothy T Lu Journal: Gut Date: 2016-09-02 Impact factor: 23.059
Authors: B Jharap; W J Sandborn; W Reinisch; G D'Haens; A M Robinson; W Wang; B Huang; A Lazar; R B Thakkar; J-F Colombel Journal: Aliment Pharmacol Ther Date: 2015-09-03 Impact factor: 8.171